Type 2 Diabetes
Nearly 62% achieve MASH resolution without worsening of fibrosis with tirzepatide
Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.
‘This is going to take all of us’: Creative partnerships can reduce cardiometabolic risk
BOSTON — Lowering cardiovascular risk for people with type 2 diabetes requires effort from far beyond the clinician’s office, leveraging creative community partnerships that address social determinants of health, according to a speaker.
FDA approves dapagliflozin for children and adolescents with type 2 diabetes
The FDA approved the SGLT2 inhibitor dapagliflozin to improve glycemic control among children and adolescents aged 10 years and older with type 2 diabetes, according to an industry press release.
FDA clears OTC CGMs for general public, adults with type 2 diabetes who do not use insulin
The FDA granted clearance for two new over-the-counter continuous glucose monitoring systems, one for adults with type 2 diabetes who do not use insulin and another for adults without diabetes, according to an industry press release.
Insurance denials may pose substantial barrier to GLP-1 drugs for teens
BOSTON — From 2019 to 2023, insurance covered GLP-1 receptor agonist prescriptions at a Texas hospital for less than 70% of young people with type 2 diabetes and less than 40% of those with obesity.
Flavonoid-rich diet may reduce risk for type 2 diabetes
Consuming more flavonoids and flavonoid-rich foods such as tea, berries and apples was associated with a lower risk for type 2 diabetes, researchers found.
Diabetes does not raise risk for subsequent hip fracture after incident fracture
Older adults with type 1 or type 2 diabetes who sustain an incident hip fracture have a similar likelihood for a subsequent hip fracture as those without diabetes, according to study data published in Bone.
Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk
Use of the drug semaglutide in patients with type 2 diabetes significantly reduced the risk of major kidney disease events, cardiovascular outcomes and all-cause mortality vs. placebo, newly published data show.
Tirzepatide lowers body weight, improves glycemic control for adults with type 1 diabetes
Adults with type 1 diabetes and overweight or obesity prescribed tirzepatide off-label had a reduction in body weight and improvements in HbA1c and continuous glucose monitoring metrics, according to data from a real-world study.
Eating more foods containing additive emulsifiers may raise risk for type 2 diabetes
Adults in France who consumed more food additive emulsifiers had increased risk for type 2 diabetes, according to a study published in The Lancet Diabetes & Endocrinology.